Cumberland Pharma announces pediatric Vibativ safety study publication

CUMBERLAND PHARMACEUTICALS INC

First clinical study of Vibativ in children 2–17; single 10 mg/kg dose safe with no serious adverse events.
Published in Antimicrobial Agents and Chemotherapy; 22 patients enrolled.
Study found lower drug exposure in children vs adults, informing future dosing.
Vibativ is FDA-approved for adult HABP/VABP and cSSSIs caused by gram-positive bacteria.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.